AI Article Synopsis

  • Antiretroviral therapy has significantly decreased HIV-related deaths, leading to more women living into menopause, but estrogen loss and HIV treatments can contribute to bone loss.
  • A study in Zimbabwe involving women aged 40-60 found a higher prevalence of osteoporosis and fractures among those living with HIV compared to those without, indicating a need for awareness and treatment options.
  • Factors such as age, weight, and HIV status were linked to lower bone mineral density and a higher probability of major osteoporotic fractures; none of the women reported using osteoporosis medications.

Article Abstract

Antiretroviral therapy roll-out has dramatically reduced HIV-related mortality; more women are living to reach menopause. Menopausal estrogen loss causes bone loss, as does HIV and some of its treatments. However, data describing HIV's impact on osteoporosis prevalence and fracture risk are scarce in southern Africa. A cross-sectional study of women aged 40-60 years (49% women with HIV [WLH]) was conducted in Harare, Zimbabwe. Menopause, fracture, and HIV history were collected, and anthropometry and BMD (by DXA) measured, and FRAX 10-year fracture probabilities quantified. The FRAX probability of a major osteoporotic fracture (MOF) included HIV as a risk factor for secondary osteoporosis. Linear and Poisson regression determined the relationships between clinical risk factors and both femoral neck (FN) BMD and the 10-year FRAX probability of MOF respectively. The 393 participants had a mean (SD) age of 49.6 (5.8) years and mean (SD) BMI of 29.1 (6.0) kg/m2. 95% of WLH were antiretroviral therapy (ART) established (85% tenofovir disoproxil fumarate) and 81% had a viral load <50 copies/mL. A BMD T-score ≤ -2.5 was more common in WLH than those without, at both FN and lumbar spine (LS) (FN, 22 [11.4%] vs 5 [2.5%]; LS, 40 [20.8%] vs 9 [4.5%], respectively). Prior fracture was more prevalent in WLH: any fracture type (27 [14%] vs 14 [7%]); MOF (14 [7.3%] vs 5 [2.5%]). WLH had a higher 10-year MOF probability (median, 1.2%; IQR, 0.9-1.8) compared with those without HIV (1.0%; IQR, 0.9-1.5) (p < .001), although probabilities were low. Older age, low weight, and HIV infection were strongly associated with lower FN BMD. Higher probability of MOF was associated with older age, HIV infection, parental hip fracture and prior fracture, although adjustment attenuated the association with HIV. No woman reported anti-osteoporosis medication use. While osteoporosis and previous fractures were common and untreated in this relatively young population, particularly in WLH, the FRAX-predicted 10-year MOF risk was low. Clinical risk factors considered in fracture risk prediction tools in Zimbabwe may need contextual modification.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11425699PMC
http://dx.doi.org/10.1093/jbmr/zjae138DOI Listing

Publication Analysis

Top Keywords

fracture risk
8
cross-sectional study
8
antiretroviral therapy
8
frax probability
8
fracture
5
prevalence hiv-associated
4
hiv-associated osteoporosis
4
osteoporosis fracture
4
risk
4
risk midlife
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!